Physician profile
Stacy D Blum
NPI 1174530976
$6,944.97
in general payments reported to CMS, 2019-2025
45 companies · $1,004 in 2025
The $1,004 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,151 · 2020: $572 · 2021: $1,099 · 2022: $911 · 2023: $1,208 · 2024: $1,000 · 2025: $1,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,212.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,143.19 | 2021-2025 | Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $917.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $832.41 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $441.93 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $414.53 | 2019-2025 | |
| Astellas Pharma US INC | $364.97 | 2019-2023 | Veozah |
| Allergan, INC. | $337.32 | 2019-2020 | |
| Novo Nordisk INC | $333.51 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $189.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.68 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.02 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $154.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $144.79 | 2021-2025 | Sotyktu, Camzyos |
| Sanofi-Aventis U.S. LLC | $143.52 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $131.98 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stacy Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.